CIRC's subsidiary's application for clinical trials of improved new drugs has been approved
China National Nuclear Corporation (01763.HK) announced that the information on the official website of the National Medical Products Administration shows that the clinical trial application for the 2.2 class improved new drug "Injectable Boron [10B] Fen" (BNCT boron drug: Boron Neutron Capture Therapy), independently developed by its subsidiary China Nuclear Haidewei, has been approved.
"Injectable Boron [10B] Fen" has significant clinical advantages for head and neck tumors that are insensitive to radiotherapy and chemotherapy, recurrent, refractory, infiltrative, in the middle to late stages, and locally metastatic, with a short treatment course (only requiring 1-2 sessions) and low toxicity and side effects
Source: AASTOCKS The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments